UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
UroGen Pharma Delivers Double Digit JELMYTO® Growth
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
UroGen Pharma to Participate at Upcoming Investor Conferences
UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
UroGen Secures Exclusive License from medac GmbH
UroGen Pharma to Participate in the B. Riley Healthcare Conference